Patients' characteristics
| No. . | Age, y . | Sex, M/F . | Diagnosis, SM variant . | KIT D816V . | Serum tryptase, ng/mL . | BM MC infiltration grade, %* . |
|---|---|---|---|---|---|---|
| 01 | 43 | M | ISM | − | 20 | 5 |
| 02 | 50 | M | ISM | + | 54 | 10 |
| 03 | 32 | M | ISM | + | 36 | 5 |
| 04 | 49 | F | ISM | + | 54 | 5 |
| 05 | 39 | F | ISM | + | 17 | 5 |
| 06 | 39 | M | ISM | + | 16 | 5 |
| 07 | 53 | M | ISM | + | 60 | 5 |
| 08 | 43 | M | ISM | + | 69 | 20 |
| 09 | 23 | F | ISM | + | 14 | 5 |
| 10 | 47 | F | ISM | + | 65 | 15 |
| 11 | 79 | M | ISM | + | 31 | 5 |
| 12 | 58 | F | ISM | − | 50 | 1 |
| 13 | 66 | M | ISM | + | 65 | 15 |
| 14 | 68 | F | ISM | + | 17 | 5 |
| 15 | 53 | F | ISM | + | 14 | 5 |
| 16 | 33 | M | ISM | + | 67 | 2 |
| 17 | 63 | F | ISM | + | 30 | 1 |
| 18 | 44 | F | ISM | + | 175 | 10 |
| 19 | 53 | M | ISM/CLL | + | 290 | 20 |
| 20 | 45 | F | ISM | + | 938 | 15 |
| 21 | 56 | M | ISM | + | 650 | 20 |
| 22 | 40 | M | SSM | + | nt | 35 |
| 23 | 42 | M | SSM | + | 630 | 40 |
| 24 | 60 | F | SSM | + | 188 | 40 |
| 25 | 55 | F | SSM | + | 133 | 20 |
| 26 | 64 | F | SSM | + | nt | 15 |
| 27 | 61 | F | ASM | − | nt | 10 |
| 28 | 48 | F | ASM | + | nt | 25 |
| 29 | 49 | F | ASM | + | nt | 30 |
| 30 | 43 | M | ASM | + | 100 | 40 |
| 31 | 46 | M | ASM/MDS | − | 421 | 30 |
| 32 | 73 | M | ASM/CMML | + | 654 | 40 |
| 33 | 71 | F | ASM/CMML | + | 295 | 60 |
| 34 | 44 | M | MCL | + | 308 | 30 |
| 35 | 66 | M | MCL/MDS | + | 763 | 70 |
| 36 | 35 | F | MCL | − | 489 | 21 |
| 37 | 26 | M | MCL | − | 2500 | 90 |
| 38 | 60 | M | MCL | + | 375 | 100 |
| No. . | Age, y . | Sex, M/F . | Diagnosis, SM variant . | KIT D816V . | Serum tryptase, ng/mL . | BM MC infiltration grade, %* . |
|---|---|---|---|---|---|---|
| 01 | 43 | M | ISM | − | 20 | 5 |
| 02 | 50 | M | ISM | + | 54 | 10 |
| 03 | 32 | M | ISM | + | 36 | 5 |
| 04 | 49 | F | ISM | + | 54 | 5 |
| 05 | 39 | F | ISM | + | 17 | 5 |
| 06 | 39 | M | ISM | + | 16 | 5 |
| 07 | 53 | M | ISM | + | 60 | 5 |
| 08 | 43 | M | ISM | + | 69 | 20 |
| 09 | 23 | F | ISM | + | 14 | 5 |
| 10 | 47 | F | ISM | + | 65 | 15 |
| 11 | 79 | M | ISM | + | 31 | 5 |
| 12 | 58 | F | ISM | − | 50 | 1 |
| 13 | 66 | M | ISM | + | 65 | 15 |
| 14 | 68 | F | ISM | + | 17 | 5 |
| 15 | 53 | F | ISM | + | 14 | 5 |
| 16 | 33 | M | ISM | + | 67 | 2 |
| 17 | 63 | F | ISM | + | 30 | 1 |
| 18 | 44 | F | ISM | + | 175 | 10 |
| 19 | 53 | M | ISM/CLL | + | 290 | 20 |
| 20 | 45 | F | ISM | + | 938 | 15 |
| 21 | 56 | M | ISM | + | 650 | 20 |
| 22 | 40 | M | SSM | + | nt | 35 |
| 23 | 42 | M | SSM | + | 630 | 40 |
| 24 | 60 | F | SSM | + | 188 | 40 |
| 25 | 55 | F | SSM | + | 133 | 20 |
| 26 | 64 | F | SSM | + | nt | 15 |
| 27 | 61 | F | ASM | − | nt | 10 |
| 28 | 48 | F | ASM | + | nt | 25 |
| 29 | 49 | F | ASM | + | nt | 30 |
| 30 | 43 | M | ASM | + | 100 | 40 |
| 31 | 46 | M | ASM/MDS | − | 421 | 30 |
| 32 | 73 | M | ASM/CMML | + | 654 | 40 |
| 33 | 71 | F | ASM/CMML | + | 295 | 60 |
| 34 | 44 | M | MCL | + | 308 | 30 |
| 35 | 66 | M | MCL/MDS | + | 763 | 70 |
| 36 | 35 | F | MCL | − | 489 | 21 |
| 37 | 26 | M | MCL | − | 2500 | 90 |
| 38 | 60 | M | MCL | + | 375 | 100 |
F indicates female; M, male; SM, systemic mastocytosis; MC, mast cell; ISM, indolent SM; CLL, chronic lymphatic leukemia; SSM smoldering SM; ASM, aggressive SM, MCL, mast cell leukemia; MDS, myelodysplastic syndrome; CMML, chronic myelomonocytic leukemia; and nt, not tested.
The percentage of infiltration of the BM by MCs was determined by tryptase IHC.